EBCC7 Conference

Barcelona—A meta-analysis of 4 large breast cancer trials reveals that a particular chromosome abnormality is a highly significant indicator that a patient’s breast cancer will respond to anthracycline therapy, announced an international team of researchers at the EBCC7 meeting.

Barcelona—An effort to monitor and modify prescription drug use in breast cancer patients prescribed tamoxifen can help prevent the polypharmacy that lessens tamoxifen’s effectiveness.

Barcelona—For women with the BRCA1 or 2 genetic mutation that predisposes them to breast cancer, the option to undergo prophylactic mastectomy of the other, noncancerous breast following their initial breast cancer treatment does not improve disease-free survival or overall survival, said researchers at the EBCC7 meeting.